(LH) Laboratory of America - Overview
Stock: Laboratory Testing, Specialty Diagnostics, Drug Development, Health Apps
| Risk 5d forecast | |
|---|---|
| Volatility | 22.6% |
| Relative Tail Risk | -5.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | 5.47 |
| Character TTM | |
|---|---|
| Beta | 0.593 |
| Beta Downside | 0.646 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.36% |
| CAGR/Max DD | 0.70 |
EPS (Earnings per Share)
Revenue
Description: LH Laboratory of America February 11, 2026
Labcorp (NYSE: LH) operates two primary businesses-Diagnostics Laboratories, which delivers a broad menu of clinical tests (e.g., blood chemistry, genetics, infectious disease, oncology and wellness panels), and Biopharma Laboratory Services, which supports drug development, companion diagnostics and specialty testing for pharma, biotech and medical-device firms.
In FY 2023 the company reported revenue of $13.9 billion, a 6 % year-over-year increase driven by a 5 % rise in test volumes and an 8 % growth in Biopharma services revenue. Adjusted EBITDA margin expanded to 10.2 % (up from 9.5 % in FY 2022), while net income reached $1.2 billion, reflecting continued cost-discipline and higher reimbursement rates for advanced molecular assays.
Key sector catalysts include the aging U.S. population, which is expanding demand for chronic-disease monitoring; the rapid adoption of high-throughput genetic and companion-diagnostic testing as personalized medicine matures; and the shift toward value-based care contracts that favor outsourced, cost-effective laboratory solutions. These macro trends underpin Labcorp’s growth outlook and its positioning within the Health Care Services sub-industry.
For a data-driven, quantitative view of LH’s valuation, the ValueRay analysis offers a concise next step.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 876.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.59 > 1.0 |
| NWC/Revenue: 8.58% < 20% (prev 11.35%; Δ -2.77% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 876.5m |
| Net Debt (6.68b) to EBITDA (2.15b): 3.11 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.2m) vs 12m ago -1.19% < -2% |
| Gross Margin: 28.24% > 18% (prev 0.28%; Δ 2796 % > 0.5%) |
| Asset Turnover: 75.88% > 50% (prev 70.78%; Δ 5.10% > 0%) |
| Interest Coverage Ratio: 6.55 > 6 (EBITDA TTM 2.15b / Interest Expense TTM 224.1m) |
Altman Z'' 3.42
| A: 0.07 (Total Current Assets 4.02b - Total Current Liabilities 2.82b) / Total Assets 18.39b |
| B: 0.47 (Retained Earnings 8.64b / Total Assets 18.39b) |
| C: 0.08 (EBIT TTM 1.47b / Avg Total Assets 18.39b) |
| D: 0.88 (Book Value of Equity 8.62b / Total Liabilities 9.76b) |
| Altman-Z'' Score: 3.42 = A |
Beneish M -2.98
| DSRI: 1.01 (Receivables 2.26b/2.10b, Revenue 13.95b/13.01b) |
| GMI: 0.99 (GM 28.24% / 27.86%) |
| AQI: 1.07 (AQ_t 0.61 / AQ_t-1 0.57) |
| SGI: 1.07 (Revenue 13.95b / 13.01b) |
| TATA: -0.04 (NI 876.5m - CFO 1.64b) / TA 18.39b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of LH shares?
Over the past week, the price has changed by +0.01%, over one month by +4.19%, over three months by +8.40% and over the past year by +14.70%.
Is LH a buy, sell or hold?
- StrongBuy: 13
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 305.9 | 8.2% |
| Analysts Target Price | 305.9 | 8.2% |
LH Fundamental Data Overview February 21, 2026
P/E Forward = 15.949
P/S = 1.6825
P/B = 2.6941
P/EG = 2.0699
Revenue TTM = 13.95b USD
EBIT TTM = 1.47b USD
EBITDA TTM = 2.15b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 695.8m USD (from shortTermDebt, last quarter)
Debt = 7.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.68b USD (from netDebt column, last quarter)
Enterprise Value = 30.15b USD (23.47b + Debt 7.21b - CCE 532.3m)
Interest Coverage Ratio = 6.55 (Ebit TTM 1.47b / Interest Expense TTM 224.1m)
EV/FCF = 25.00x (Enterprise Value 30.15b / FCF TTM 1.21b)
FCF Yield = 4.00% (FCF TTM 1.21b / Enterprise Value 30.15b)
FCF Margin = 8.64% (FCF TTM 1.21b / Revenue TTM 13.95b)
Net Margin = 6.28% (Net Income TTM 876.5m / Revenue TTM 13.95b)
Gross Margin = 28.24% ((Revenue TTM 13.95b - Cost of Revenue TTM 10.01b) / Revenue TTM)
Gross Margin QoQ = 26.18% (prev 28.77%)
Tobins Q-Ratio = 1.64 (Enterprise Value 30.15b / Total Assets 18.39b)
Interest Expense / Debt = 0.76% (Interest Expense 55.0m / Debt 7.21b)
Taxrate = 13.48% (25.7m / 190.6m)
NOPAT = 1.27b (EBIT 1.47b * (1 - 13.48%))
Current Ratio = 1.42 (Total Current Assets 4.02b / Total Current Liabilities 2.82b)
Debt / Equity = 0.84 (Debt 7.21b / totalStockholderEquity, last quarter 8.62b)
Debt / EBITDA = 3.11 (Net Debt 6.68b / EBITDA 2.15b)
Debt / FCF = 5.54 (Net Debt 6.68b / FCF TTM 1.21b)
Total Stockholder Equity = 8.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.77% (Net Income 876.5m / Total Assets 18.39b)
RoE = 10.28% (Net Income TTM 876.5m / Total Stockholder Equity 8.52b)
RoCE = 10.79% (EBIT 1.47b / Capital Employed (Equity 8.52b + L.T.Debt 5.08b))
RoIC = 9.03% (NOPAT 1.27b / Invested Capital 14.07b)
WACC = 6.35% (E(23.47b)/V(30.68b) * Re(8.10%) + D(7.21b)/V(30.68b) * Rd(0.76%) * (1-Tc(0.13)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.01%
[DCF Debug] Terminal Value 82.54% ; FCFF base≈1.16b ; Y1≈992.5m ; Y5≈766.8m
Fair Price DCF = 165.0 (EV 20.35b - Net Debt 6.68b = Equity 13.68b / Shares 82.9m; r=6.35% [WACC]; 5y FCF grow -17.70% → 2.90% )
EPS Correlation: -43.21 | EPS CAGR: -10.27% | SUE: 1.87 | # QB: 4
Revenue Correlation: 29.85 | Revenue CAGR: -2.73% | SUE: -1.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.13 | Chg30d=+0.016 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=17.73 | Chg30d=+0.207 | Revisions Net=+1 | Growth EPS=+7.8% | Growth Revenue=+5.2%
EPS next Year (2027-12-31): EPS=19.27 | Chg30d=+0.075 | Revisions Net=+1 | Growth EPS=+8.7% | Growth Revenue=+4.8%